Crinetics Pharmaceuticals, Inc. 4

Wendell Wierenga had all of his Crinetics Pharmaceuticals, Inc. common stock, RSUs, and in-the-money stock options canceled and cashed out at the $85.00-per-share merger price on 2026-09-01.

On September 1, 2026, in connection with the closing of the cash merger of Crinetics Pharmaceuticals, Inc. into a Vertex Pharmaceuticals subsidiary at $85.00 per share, all of Wendell Wierenga’s equity in Crinetics was canceled and cashed out. His 116,146 shares of common stock and 5,925 restricted stock units were converted into the right to receive $85.00 per share in cash, for an estimated $9.87 million of stock and $0.50 million of RSUs. In addition, multiple tranches of vested stock options with exercise prices below $85.00 (covering 125,000+ shares across grants with per-share spreads of $61.76, $61.77, $64.77, $66.71, $64.68, $40.29, $52.67, and $49.13) were canceled and converted into cash equal to the difference between $85.00 and the respective exercise prices, generating an estimated incremental option value of roughly $8.3 million. All Crinetics equity awards were extinguished in the merger, leaving Wierenga with no remaining holdings of the issuer’s securities, and the transactions reflect compensation and liquidity realization driven by the change‑of‑control rather than open‑market trading activity.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059910

Alert Tier

7